TapImmune Inc. (OTCMKTS:TPIV) Back Under a Dollar

After an eventful end of June with a lot of heated price action on the charts, TapImmune Inc. (OTCMKTS:TPIV) is now cooling down. Yesterday the company’s stock dropped 7.8% to stop below the one dollar dividing line once more. Volume remained relatively restrained, at 808 thousand shares traded over the session.

It almost looked like it would be smooth sailing yesterday, with TPIV back over a dollar and holding a steady course for a couple of days. However, in the afternoon the price took a bit of a nose dive and TPIV found itself back under a dollar.

The company kept a very low profile during the red streak that wiped a significant part of its new, significantly inflated market cap. TPIV‘s last official press announcement was that of the successful tests in breast cancer patients, published on June 23.

All things considered, TPIV is still a volatile investment choice. The company’s excursion from around $0.20 per share all the way up to $1.50 has no doubt led to profit taking. The 40% slip that brought TPIV to just $0.90 per share a few days ago is no laughing matter, especially for traders who tried to chase the ticker up the chart and got in late.

The stock returned to regular trading ranges but even a hike from $0.20 to $0.90 might prove difficult to sustain in the absence of more positive PR. TPIV‘s next quarterly is due by mid-August.

TPIV is currently another 4% down in early trading.